[go: up one dir, main page]

AU2003246592A1 - Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases - Google Patents

Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases

Info

Publication number
AU2003246592A1
AU2003246592A1 AU2003246592A AU2003246592A AU2003246592A1 AU 2003246592 A1 AU2003246592 A1 AU 2003246592A1 AU 2003246592 A AU2003246592 A AU 2003246592A AU 2003246592 A AU2003246592 A AU 2003246592A AU 2003246592 A1 AU2003246592 A1 AU 2003246592A1
Authority
AU
Australia
Prior art keywords
tumour
diagnosis
treatment
diseases
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003246592A
Inventor
Marie-Laure Fogeron
Udo Kellner
Hermann Lage
Stephanie Lamer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EUROPROTEOME AG
Original Assignee
EUROPROTEOME AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EUROPROTEOME AG filed Critical EUROPROTEOME AG
Publication of AU2003246592A1 publication Critical patent/AU2003246592A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/24—Extraction; Separation; Purification by electrochemical means
    • C07K1/26—Electrophoresis
    • C07K1/28—Isoelectric focusing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2003246592A 2002-06-26 2003-06-26 Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases Abandoned AU2003246592A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10229386 2002-06-26
DE10229386.4 2002-06-26
PCT/EP2003/006748 WO2004003564A2 (en) 2002-06-26 2003-06-26 Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases

Publications (1)

Publication Number Publication Date
AU2003246592A1 true AU2003246592A1 (en) 2004-01-19

Family

ID=29796039

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003246592A Abandoned AU2003246592A1 (en) 2002-06-26 2003-06-26 Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases

Country Status (2)

Country Link
AU (1) AU2003246592A1 (en)
WO (1) WO2004003564A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0507039A8 (en) 2004-01-22 2018-12-18 Univ Miami composition, methods of treating a cancer patient, and inhibiting angiogenesis in a tumor, and
EP2136787B1 (en) 2007-03-22 2019-08-21 Berg LLC Topical formulations having enhanced bioavailability
JP6058263B2 (en) 2008-04-11 2017-01-11 バーグ リミテッド ライアビリティ カンパニー Methods and uses for inducing apoptosis in cancer cells
AU2008360729A1 (en) * 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase
MX357528B (en) 2009-05-11 2018-07-13 Berg Llc METHODS FOR THE TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC EXCHANGERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES OR ENVIRONMENTAL INFLUENCES.
NZ720022A (en) 2010-03-12 2018-07-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
CN103608323B (en) 2011-04-04 2016-08-17 博格有限责任公司 The method for the treatment of central nerve neuroma
MX369543B (en) 2011-06-17 2019-11-12 Berg Llc Inhalable pharmaceutical compositions.
CA2909094C (en) 2013-04-08 2023-06-27 Berg Llc Methods for the treatment of cancer using coenzyme q10 combination therapies
MX381399B (en) 2013-09-04 2025-03-12 Berg Llc COENZYME Q10 FORMULATIONS AND METHODS OF USE.
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001264559A1 (en) * 2000-06-05 2001-12-17 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Also Published As

Publication number Publication date
WO2004003564A2 (en) 2004-01-08
WO2004003564A3 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003291992A1 (en) Phenylethanolamine derivatives for the treatment of respiratory diseases
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1578421A4 (en) Pharmaceutical preparations for treatments of diseases and disorders of the breast
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2002226690A1 (en) Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003209150A1 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
AU2003245927A1 (en) Target genes for the diagnosis and treatment of cancer
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
AU2002364501A1 (en) Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
AU2003230849A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2003250912A1 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003263036A1 (en) SPAN-Xb GENE AND PROTEIN FOR THE DIAGNOSIS AND TREATMENT OF CANCER
WO2005052191A8 (en) Compositions and methods for the diagnosis and treatment of tumor
GB0201025D0 (en) The treatment of degenerative diseases
AU2003274649A1 (en) Diagnostic markers for therapeutic treatment
AU2003288127A1 (en) DIAGNOSTIC AND THERAPEUTIC USE OF H-Rev107 PROTEIN FOR ALZHEIMER DISEASE

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase